Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Nicotinamide Riboside (NR) significantly reduced hair loss for the user. They found science.bio's NR to be effective, unlike other brands.

Some people have low sulfotransferase enzyme levels, affecting their response to minoxidil. Lifestyle factors, genetics, and diet, like MSM intake, might influence these enzyme levels.

The user has been inconsistently using a 0.1% finasteride and 5% minoxidil topical treatment for hair loss over the past nine months, along with 1% Nizoral once a week. They aim to improve consistency in their treatment this year and report no side effects.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.

The conversation is about determining which type of Saw Palmetto, either Chamaerops humilis or Serenoa repens, is effective for inhibiting the 5 alpha reductase enzyme related to hair loss. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

A user is seeking a hair loss formula containing Redensyl and Capixyl without caffeine, Saw Palmetto, or other herbs. They want recommendations for such a product.

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation is about a user's progress in treating hair loss using 1mg finasteride, topical minoxidil once at night, and weekly 1.5mm microneedling. The user reports significant improvement and no side effects, while others discuss their experiences and offer advice on similar treatments.

An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.

A user shared progress pictures after 7 months on 1.5mg of finasteride, showing significant hair improvement. The user clarified they split 5 mg pills into quarters, resulting in a 1.33 mg dose.

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.

Microneedling depth should be customized based on hair type and scalp area, with many users finding 0.5-0.6mm effective for miniaturized hairs to avoid damage. Users report varying pain levels and results, with some preferring shorter needle lengths and others using longer ones like 1.75mm for scalp health and density improvement.

User shared 4-month progress on hair loss treatment using 0.25mg finasteride daily and topical minoxidil daily, noting cognitive decline possibly linked to finasteride. Users discussed side effects, alternative treatments, and shared similar experiences.

The user is considering starting dutasteride (DUT) 0.5mg for hair loss due to lack of access to finasteride and is concerned about potential side effects. They seek guidance on whether to begin this treatment.

A 23-year-old male with Norwood 2.5-3 hair loss is considering using a lotion containing 0.3% finasteride and 6% minoxidil spray, as recommended by a dermatologist. He is hesitant about using oral finasteride due to potential long-term side effects.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

A 34-year-old man plans to reduce his finasteride dose from 1 mg to 0.5 mg due to negative side effects like hormonal imbalances and seeks advice on managing these effects and potential alternatives. Suggestions include considering dutasteride as an alternative and noting that a new equilibrium with a reduced dose may take about two weeks.

The user is treating male pattern baldness with oral minoxidil, ketoconazole, derma rolling, rosemary oil, and topical minoxidil, and is considering adding finasteride. They are debating between three finasteride dosing strategies: 1mg daily, 1.25mg every other day, or 1.25mg five days a week, focusing on efficacy, safety, and cost.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The user is concerned about worsening hair loss after 9 months on 1.25 mg finasteride, with suggestions to add minoxidil and consider dutasteride. Some users report decreased shedding with different treatments, while others note possible issues with photo comparisons.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.